• About
  • Tests
  • News
  • Contact
  • Order Tests
ORDER TESTS
Annual Association For Molecular Pathology Presentation

Annual Association For Molecular Pathology Presentation

by Jean Rodriguez | Feb 14, 2024 | Healthcare

Precision Epigenomics Inc. presents a bioinformatics study…
Digestive Disease Week Presentation

Digestive Disease Week Presentation

by Jean Rodriguez | Feb 10, 2024 | Healthcare

Precision Epigenomics Inc. presents a pilot study of the performance of EPISEEK™ for hepatocellular carcinoma at the Digestive Disease Week Annual Meeting 2023 in Chicago
American Thoracic Society Presentation

American Thoracic Society Presentation

by Jean Rodriguez | Feb 8, 2024 | Healthcare

Precision Epigenomics Inc. presents results of the performance of the EPISEEK-MPE™ test at the annual American Thoracic Society meeting 2023 in Washington, DC
National Human Genome Research Training Grant

National Human Genome Research Training Grant

by Jean Rodriguez | Jan 20, 2024 | Industry

Precision Epigenomics Inc. and Arizona State University collaborators are awarded a training grant by National Human Genome Research Institute to train students in bioinformatics through the Training in Genomics Research program
Molecular Test for Indeterminate Melanoma Lesions Pilot Program

Molecular Test for Indeterminate Melanoma Lesions Pilot Program

by Jean Rodriguez | Aug 14, 2023 | Diagnosis

Precision Epigenomics Inc. and University of Arizona collaborators awarded a pilot project to develop a new molecular test for indeterminate melanoma lesions
« Older Entries

Recent Posts

  • 2024 Flinn Foundation Bioscience Entrepreneurship Program Partner
  • Annual Association For Molecular Pathology Presentation
  • Digestive Disease Week Presentation
  • Multi-Cancer Detection Assay on Pleural Fluid Publication
  • American Thoracic Society Presentation

Recent Comments

No comments to show.

The EPISEEK test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The EPISEEK test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. EPISEEK is intended to detect cancer signals. Use of EPISEEK is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present (i.e. EPISEEK false positive) or confirmatory testing was insufficient to detect cancer (follow up testing false negative). False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Quick Links

Home
About
Tests
News
Contact

Other Pages

Privacy Policy
Terms & Conditions
FCOI

Contact Info



630 N Alvernon Way
Ste 280B
Tucson, AZ 85711



520.372.7522